Home >> Research Area >>MAPK Signaling>>Raf>> B-Raf inhibitor

B-Raf inhibitor

A B-Raf inhibitor CAS# 1315330-11-0

B-Raf inhibitor

Catalog No. BCC1437----Order now to get a substantial discount!

Product Name & Size Price Stock
B-Raf inhibitor: 5mg $322 In Stock
B-Raf inhibitor: 10mg Please Inquire In Stock
B-Raf inhibitor: 20mg Please Inquire Please Inquire
B-Raf inhibitor: 50mg Please Inquire Please Inquire
B-Raf inhibitor: 100mg Please Inquire Please Inquire
B-Raf inhibitor: 200mg Please Inquire Please Inquire
B-Raf inhibitor: 500mg Please Inquire Please Inquire
B-Raf inhibitor: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of B-Raf inhibitor

Number of papers citing our products

Chemical structure

B-Raf inhibitor

3D structure

Chemical Properties of B-Raf inhibitor

Cas No. 1315330-11-0 SDF Download SDF
PubChem ID 71254032 Appearance Powder
Formula C29H31F3N6O2 M.Wt 552.59
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 50 mg/mL (90.48 mM; Need ultrasonic)
Chemical Name N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]benzamide
SMILES CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=NC=NC5=C4C=C(N5)C)C(F)(F)F
Standard InChIKey RWNAOXLCVXJMGM-UHFFFAOYSA-N
Standard InChI InChI=1S/C29H31F3N6O2/c1-4-37-9-11-38(12-10-37)16-21-7-8-22(15-24(21)29(30,31)32)36-27(39)20-6-5-18(2)25(14-20)40-28-23-13-19(3)35-26(23)33-17-34-28/h5-8,13-15,17H,4,9-12,16H2,1-3H3,(H,36,39)(H,33,34,35)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of B-Raf inhibitor

DescriptionA B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.

References:
[1]. Gray, Nathanael S. Preparation of pyrazine and pyrrolo[2,3-b]pyridine derivatives as b-raf kinase inhibitors useful in the treatment of cancer and proliferative diseases. PCT Int. Appl. (2011), WO 2011090738 A2 20110728.

B-Raf inhibitor Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

B-Raf inhibitor Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of B-Raf inhibitor

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.8097 mL 9.0483 mL 18.0966 mL 36.1932 mL 45.2415 mL
5 mM 0.3619 mL 1.8097 mL 3.6193 mL 7.2386 mL 9.0483 mL
10 mM 0.181 mL 0.9048 mL 1.8097 mL 3.6193 mL 4.5241 mL
50 mM 0.0362 mL 0.181 mL 0.3619 mL 0.7239 mL 0.9048 mL
100 mM 0.0181 mL 0.0905 mL 0.181 mL 0.3619 mL 0.4524 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on B-Raf inhibitor

A B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.

Featured Products
New Products
 

References on B-Raf inhibitor

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.[Pubmed:27371224]

Cancer Chemother Pharmacol. 2016 Aug;78(2):419-26.

PURPOSE: Vemurafenib (VMF) is a B-Raf inhibitor used in the treatment of B-RAF-V600-mutant metastatic melanomas. Reports of acute kidney injury (AKI) in patients treated with VMF are scarce. METHODS: To investigate the incidence and severity of AKI, we conducted a retrospective, observational, monocentric study in the Lyon Sud Hospital University, France, which included 74 patients with metastatic B-RAF-mutated melanomas treated with VMF, between June 2011 and August 2014. According to the Kidney Disease Improving Global Outcomes Guidelines, AKI is defined as an increase in serum creatinine concentration exceeding the baseline concentration by 1.5 fold. Serum creatinine was thus determined before treatment, on a monthly basis during treatment, and 3 months after treatment discontinuation. Patients were divided into two main groups: AKI-positive (AKI+) and AKI-negative (AKI-) and further subdivided into three groups according to AKI severity (stage 1, 2 or 3). To visualize the tissue damage caused by VMF, kidney biopsies were performed for two stage 1 AKI+ patients. RESULTS: Of the 74 patients, 30 (40.5 %) were AKI-, and of the 44 AKI+ patients (59.5 %), 29 (66 %) were diagnosed within the first three months of treatment. There were significantly more men in the AKI+ group: n = 33 (75 %) versus n = 12 (40 %) women, p = 0.004 with an odds ratio for developing AKI of 4.6 (95 % CI 1.48-14.23). Most AKI + cases were considered as stage 1 (n = 40; 91 %) and the remaining four (9 %) as stage 2 AKI. Kidney biopsies revealed interstitial fibrosis and acute focal tubular damage. However, renal failure was reversible in 80 % of patients within 3 months of VMF discontinuation. CONCLUSIONS: We observed frequent, reversible, moderately severe AKI with some histological evidence of tubular and interstitial damage in VMF-treated patients, suggesting that renal function should be carefully monitored in male patients, especially during the first 3 months.

Determination of a novel B-Raf(V600E) and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study.[Pubmed:27423011]

J Pharm Biomed Anal. 2016 Sep 10;129:142-147.

The EGFR and B-Raf(V600E) dual inhibition is a promising strategy in treatment of colorectal cancer patients with B-Raf(V600E) mutation. Previously, compound 3 was designed and synthesized as a novel B-Raf(V600E) and EGFR dual inhibitor with highly potency in both kinase and cell based assay. Herein, a sensitive and rapid HPLC-MS/MS quantitative method was developed and validated for the further pharmacokinetic evaluation of compound 3 in rats.

Description

TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.

Keywords:

B-Raf inhibitor,1315330-11-0,Natural Products,Raf, buy B-Raf inhibitor , B-Raf inhibitor supplier , purchase B-Raf inhibitor , B-Raf inhibitor cost , B-Raf inhibitor manufacturer , order B-Raf inhibitor , high purity B-Raf inhibitor

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: